In a whirlwind of diabetes news, a glimmer of hope for reducing diabetes complications.

On April 3, an FDA Advisory Committee voted an overwhelming 13-1 in favor of approving MannKind’s ultra-rapid-acting inhaled insulin Afrezza for type 1 diabetes. The...

This November will be the third annual World Diabetes Day Postcard Exchange, where people from around the world will send and receive handmade postcards to celebrate...

On January 13, J&J LifeScan announced the launch of the OneTouch VerioSync blood glucose meter in the US. The meter sends blood glucose readings wirelessly (via...

On April 17, Abbott announced a recall of the FreeStyle InsuLinx blood glucose meters due to software issues for readings of 1,024 mg/dl and above. The problem is...

(S)he said what!?

Eli Lilly announced in October the submission of dulaglutide, its once-weekly GLP-1 receptor agonist for type 2 diabetes, in the US and Europe. This means a regulatory...

Six inspiring lessons learned over the last decade at the Behavioral Diabetes Institute.

We’re super proud to see our home city of San Francisco taking a stand against soda and sugary beverages and recognizing their role in the rising rates of obesity and...

The International Diabetes Federation (IDF) is holding the Take a Step for Diabetes campaign to increase awareness for diabetes. This “step” can be a variety of actions...

On July 30, Ambio Health announced FDA clearance of its Remote Health Monitoring System , which can wirelessly send readings from the AgaMatrix Presto blood glucose...

We ask ACA expert Dr. Jack Lord all the hard questions on healthcare coverage and reimbursement.

On November 22, J&J/Janssen Cilags’ SGLT-2 inhibitor Invokana (canagliflozin) was approved in Europe. This makes Invokana the second SGLT-2 inhibitor approved in...

(S)he said what!?

On April 15, the FDA approved GlaxoSmithKline’s once-weekly GLP-1 agonist Tanzeum (albiglutide) for type 2 diabetes, which makes it the second once-weekly GLP-1 agonist...

At the recent 2013 European Association for the Study of Diabetes (EASD) conference, Abbott debuted a new diabetes technology category called Flash Glucose Monitoring...

Introducing The diaTribe Foundation!

On January 21, Glooko and Joslin announced a partnership to develop a new web/mobile-based diabetes management platform. The system will combine a “Virtual Joslin”...

On March 25, Lilly and Boehringer Ingelheim (BI) announced that they submitted an application to the FDA for empagliflozin, an SGLT-2 inhibitor, for type 2 diabetes...

Five key insights from April’s big-deal artificial pancreas meeting in Washington, DC.